Silvie Huijben

Last updated
Silvie Huijben
Alma mater Wageningen University and Research
University of Edinburgh
Known for Antimalarial resistance and insecticide resistance
Scientific career
Fields Evolutionary biologist, disease ecologist, malariologist
Institutions Arizona State University
Pennsylvania State University
Barcelona Biomedical Research Park (ISGlobal)

Silvie Huijben is an evolutionary biologist and assistant professor at Arizona State University. [1] [2] The Huijben Lab uses fieldwork, lab experiments, and mathematical modeling to study antimalarial and insecticide resistance in parasites, such as disease-transmitting mosquitoes. [2] [3] [4] [5] Her work is focused on applying evolutionary theory to produce resistance management strategies to best combat malaria. [6] [7] [8]

Contents

Education

Huijben received a PhD in cell, animal and population biology from the University of Edinburgh, UK (October 2006 to January 2010). [1] She received a MSc in biology from Wageningen University, Netherlands (June 2003 to August 2006) and a BSc in biology (September 2000 to November 2004). [1]

Career

After completing her PhD in 2010, Huijben worked as a post-doctoral scholar at the Center for Infectious Disease Dynamics (CIDD), Pennsylvania State University, USA where she used a rodent malaria model to study the evolution of drug resistance. [1] [9] [10] In November 2013 she began work as a post-doctoral fellow at Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. [1] In June 2017 she became an Assistant Research Professor at ISGlobal before moving on to an assistant professor role at the Center for Evolution and Medicine, Arizona State University, USA in March 2018. [1]

She has been an editorial board member of PLOS ONE since July 2018.

Public engagement and media

Huijben has appeared on 2Scientists, [11] was a panelist on a Virtual Keystone Symposia, [12] and was featured on MESA presenting her research for the 67th ASTMH annual meeting. [13]

Research

The Huijben Lab focuses on the key question: how can we use evolutionary theory to better design resistance management strategies?. [2] [1] The lab's current research projects are centered around: [2] [6] [3] [7] [14]

  1. understanding the relation between insecticide resistance and malaria epidemiology
  2. determining optimal insecticide resistance management strategies
  3. determining optimal antimalarial resistance management strategies
  4. understanding insecticide resistance patterns in the field

Awards and recognition

In 2013, she was a recipient of the Marie Curie International Incoming Fellowship, [15] and the Society in Science – Branco Weiss Fellowship [16] to pursue her research in the evolution of drug and insecticide resistance.

In 2020, Dr. Huijben earned the Centennial Professorship Award [17] at Arizona State University for her unique dedication to biological pedagogy. [18]

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

Antimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women. As of 2018, modern treatments, including for severe malaria, continued to depend on therapies deriving historically from quinine and artesunate, both parenteral (injectable) drugs, expanding from there into the many classes of available modern drugs. Incidence and distribution of the disease is expected to remain high, globally, for many years to come; moreover, known antimalarial drugs have repeatedly been observed to elicit resistance in the malaria parasite—including for combination therapies featuring artemisinin, a drug of last resort, where resistance has now been observed in Southeast Asia. As such, the needs for new antimalarial agents and new strategies of treatment remain important priorities in tropical medicine. As well, despite very positive outcomes from many modern treatments, serious side effects can impact some individuals taking standard doses.

<i>Plasmodium</i> Genus of parasitic protists that can cause malaria

Plasmodium is a genus of unicellular eukaryotes that are obligate parasites of vertebrates and insects. The life cycles of Plasmodium species involve development in a blood-feeding insect host which then injects parasites into a vertebrate host during a blood meal. Parasites grow within a vertebrate body tissue before entering the bloodstream to infect red blood cells. The ensuing destruction of host red blood cells can result in malaria. During this infection, some parasites are picked up by a blood-feeding insect, continuing the life cycle.

<span class="mw-page-title-main">Artemisinin</span> Group of drugs used against malaria

Artemisinin and its semisynthetic derivatives are a group of drugs used in the treatment of malaria due to Plasmodium falciparum. It was discovered in 1972 by Tu Youyou, who shared the 2015 Nobel Prize in Physiology or Medicine for her discovery. Artemisinin-based combination therapies (ACTs) are now standard treatment worldwide for P. falciparum malaria as well as malaria due to other species of Plasmodium. Artemisinin is extracted from the plant Artemisia annua a herb employed in Chinese traditional medicine. A precursor compound can be produced using a genetically engineered yeast, which is much more efficient than using the plant.

<span class="mw-page-title-main">Malaria Atlas Project</span> Academic group

The Malaria Atlas Project (MAP) is a nonprofit academic group led by Peter Gething, Kerry M Stokes Chair in Child Health, at the Telethon Kids Institute, Perth, Western Australia. The group is funded by the Bill and Melinda Gates Foundation, with previous funding also coming from the Medical Research Council and the Wellcome Trust. MAP aims to disseminate free, accurate, and up-to-date information on malaria and associated topics, organised on a geographical basis. The work of MAP falls into three areas:

<span class="mw-page-title-main">History of malaria</span> History of malaria infections

The history of malaria extends from its prehistoric origin as a zoonotic disease in the primates of Africa through to the 21st century. A widespread and potentially lethal human infectious disease, at its peak malaria infested every continent except Antarctica. Its prevention and treatment have been targeted in science and medicine for hundreds of years. Since the discovery of the Plasmodium parasites which cause it, research attention has focused on their biology as well as that of the mosquitoes which transmit the parasites.

<span class="mw-page-title-main">Mosquito-borne disease</span> Diseases caused by bacteria, viruses or parasites transmitted by mosquitoes

Mosquito-borne diseases or mosquito-borne illnesses are diseases caused by bacteria, viruses or parasites transmitted by mosquitoes. Nearly 700 million people get a mosquito-borne illness each year, resulting in over tens million deaths. The devastation is almost equivalent to the entire 3 year COVID-19 global pandemic.

<span class="mw-page-title-main">Mass drug administration</span>

The administration of drugs to whole populations irrespective of disease status is referred to as mass drug administration (MDA) or mass dispensing.

Pregnancy-associated malaria (PAM) or placental malaria is a presentation of the common illness that is particularly life-threatening to both mother and developing fetus. PAM is caused primarily by infection with Plasmodium falciparum, the most dangerous of the four species of malaria-causing parasites that infect humans. During pregnancy, a woman faces a much higher risk of contracting malaria and of associated complications. Prevention and treatment of malaria are essential components of prenatal care in areas where the parasite is endemic – tropical and subtropical geographic areas. Placental malaria has also been demonstrated to occur in animal models, including in rodent and non-human primate models.

Jonathan James Juliano is an American physician/scientist. He currently works at UNC School of Medicine.

<span class="mw-page-title-main">Janet Hemingway</span> British infectious diseases specialist

Janet Hemingway is a British infectious diseases specialist. She is the former Director of Liverpool School of Tropical Medicine (LSTM) and founding Director of Infection Innovation Consortium and Professor of Tropical Medicine at LSTM. She is current President of the Royal Society of Tropical Medicine and Hygiene.

<span class="mw-page-title-main">Leann Tilley</span> Australian biochemist and microbiologist

Leann Tilley is Professor of Biochemistry and Molecular Biology in the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne.

<span class="mw-page-title-main">Andrew F. Read</span>

Andrew Fraser Read FRS is Evan Pugh professor of biology and entomology at Pennsylvania State University and the Director of the Huck Institutes of the Life Sciences.

<span class="mw-page-title-main">Elizabeth A. Winzeler</span> American microbiologist

Elizabeth Ann Winzeler is an American microbiologist and geneticist. She is a professor in the Division of Host-Microbe Systems and Therapeutics of the School of Medicine at the University of California at San Diego. Although she works in a variety of different disease areas, most research focuses on developing better medicines for the treatment and eradication of malaria.

Alan Frederick Cowman AC, FRS, FAA, CorrFRSE, FAAHMS, FASP, FASM is an internationally acclaimed malaria researcher whose work specialises in researching the malaria-causing parasite, Plasmodium falciparum, and the molecular mechanisms it uses to evade host responses and antimalarial drugs. As of May 2024, he is the deputy directory and Laboratory Head of the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, and his laboratory continues to work on understanding how Plasmodium falciparum, infects humans and causes disease. He was elected as a fellow of the Royal Society in 2011 and awarded the Companion of the Order of Australia in 2019 for his "eminent service to the biological sciences, notably to molecular parasitology, to medical research and scientific education, and as a mentor."

<span class="mw-page-title-main">Fredros Okumu</span> Kenyan parasitologist and entomologist

Fredros Okumu is a Kenyan parasitologist and entomologist, who currently works as director of science at the Ifakara Health Institute (IHI) in Tanzania. His primary research interests concern the interactions between humans and mosquitoes.

<span class="mw-page-title-main">Flaminia Catteruccia</span> Italian professor of immunology and infectious disease

Flaminia Catteruccia is an Italian professor of immunology and infectious disease at the Harvard T.H. Chan School of Public Health, studying the interactions between malaria and the Anopheles mosquitoes that transmit the parasites.

<span class="mw-page-title-main">Carolina Barillas-Mury</span> Microbiologist

Carolina Barillas-Mury is the chair of the Mosquito Immunity and Vector Competence Section and Director of the Malaria Research Program at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. She studies how mosquitos transmit diseases like malaria, and in recognition of her research, she has been elected to the National Academy of Sciences.

Heather Margaret Ferguson FRSE, Professor of Medical Entomology and Disease Ecology, at Glasgow University; a specialist in researching mosquito vectors that spread malaria, in global regions where this is endemic, aiming to manage and control a disease which the World Health Organization estimates killed over 400,000 people in 2020. Ferguson co-chairs the WHO Vector Control Advisory Group and was elected as a Fellow of the Royal Society of Edinburgh in 2021.

<span class="mw-page-title-main">David A. Fidock</span>

David A. Fidock, is the CS Hamish Young Professor of Microbiology and Immunology and Professor of Medical Sciences at Columbia University Irving Medical Center in Manhattan.

References

  1. 1 2 3 4 5 6 7 "Silvie Huijben | School of Life Sciences". sols.asu.edu. Retrieved 2019-05-04.
  2. 1 2 3 4 "The Huijben Lab – Center for Evolution and Medicine – Arizona State University". www.huijbenlab.net. Retrieved 2019-05-04.
  3. 1 2 Huijben, Silvie; Paaijmans, Krijn P. (2018). "Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites". Evolutionary Applications. 11 (4): 415–430. doi:10.1111/eva.12530. PMC   5891050 . PMID   29636796.
  4. ↑ Read, Andrew F.; Day, Troy; Huijben, Silvie (28 June 2011). "The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy". Proceedings of the National Academy of Sciences of the United States of America. 108 (Suppl 2): 10871–10877. Bibcode:2011PNAS..10810871R. doi: 10.1073/pnas.1100299108 . PMC   3131826 . PMID   21690376.
  5. ↑ "Silvie Huijben – Grants — Arizona State University". asu.pure.elsevier.com.
  6. 1 2 Resistance, The malERA Refresh Consultative Panel on Insecticide and Drug (30 November 2017). "malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication". PLOS Medicine. 14 (11): e1002450. doi: 10.1371/journal.pmed.1002450 . PMC   5708661 . PMID   29190671.
  7. 1 2 "Scopus preview - Scopus - Author details (Huijben, Silvie)". www.scopus.com.
  8. ↑ Huijben, Silvie; Bell, Andrew S.; Sim, Derek G.; Tomasello, Danielle; Mideo, Nicole; Day, Troy; Read, Andrew F. (2013). "Aggressive Chemotherapy and the Selection of Drug Resistant Pathogens". PLOS Pathogens. 9 (9): e1003578. doi: 10.1371/journal.ppat.1003578 . PMC   3771897 . PMID   24068922.
  9. ↑ "public health - New research findings from Princeton University". blogs.princeton.edu. 6 April 2016.
  10. ↑ Huijben, Silvie; Chan, Brian H K.; Nelson, William A.; Read, Andrew F. (2018). "The impact of within-host ecology on the fitness of a drug-resistant parasite". Evolution, Medicine, and Public Health. 2018 (1): 127–137. doi:10.1093/emph/eoy016. PMC   6061792 . PMID   30087774.
  11. ↑ FM, Player (31 January 2016). "Making It Hard To Resist 2Scientists podcast". player.fm. Retrieved 2019-05-04.
  12. ↑ Malaria: From Innovation to Eradication , retrieved 2019-05-04
  13. ↑ "ASTMH 2018, Silvie Huijben: "Putting evolution in elimination: winning our ongoing battle with evolving malaria mosquitoes and parasites" | Mesa". mesamalaria.org. Retrieved 2019-05-04.
  14. ↑ Lambert, Jonathan (16 January 2019). "Bacteria In Worms Make A Mosquito Repellent That Might Beat DEET". NPR.org.
  15. ↑ "Silvie Huijben receives Marie Skłodowska-Curie fellowship". The Branco Weiss Fellowship - Society in Science.
  16. ↑ "Alumni Profiles". The Branco Weiss Fellowship - Society in Science.
  17. ↑ "Centennial Professorship Award". Arizona State University.
  18. ↑ "ASU Professor Wins Centennial Professorship Award". ASU Now: Access, Excellence, Impact. 7 April 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.